CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 19,550 shares at $10.06 ($196,673)
- 4 Open-market sale 10% owner sold 73,955 shares at an average $10.12 ($748,140)
- 4 Open-market sale 10% owner sold 42,105 shares at an average $10.06 ($423,557)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Interim CEO acquired 15,211 shares (option exercise)
- 4 Open-market buy Interim CEO bought 8,288 shares at an average $4.96 ($41,078)
- 4 Open-market buy Chief Financial Officer and VP bought 25,959 shares at an average $4.48 ($116,223)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 17,121 shares at an average $4.86 ($83,177)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 11 of 14 · 271 filings